300006.SZ SHZ
Chongqing Lummy Pharmaceutical Co., Ltd.
1W: +0.0%
1M: -2.6%
3M: +11.9%
YTD: +8.2%
1Y: +9.0%
3Y: +62.1%
5Y: -23.0%
¥5.56 ($0.83)
+0.26 (+4.91%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$769M
-3.3% ▼
5Y CAGR: -13.5%
Gross Profit
$389M
-22.0% ▼
5Y CAGR: -18.4%
Operating Income
-$102M
+4.0% ▲
Net Income
-$135M
-53.4% ▼
EPS (Diluted)
$-0.13
-56.3% ▼
EBITDA
-$48M
-212.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $885M | $896M | $796M | $769M |
| YoY Growth | -22.6% | -27.8% | +1.2% | -11.2% | -3.3% |
| Cost of Revenue | $350M | $234M | $283M | $283M | $380M |
| Gross Profit | $876M | $650M | $612M | $512M | $389M |
| Gross Margin | 71.5% | 73.5% | 68.4% | 64.4% | 50.6% |
| R&D Expenses | $100M | $81M | $94M | $65M | $61M |
| SG&A Expenses | $766M | $570M | $463M | $402M | $413M |
| Operating Expenses | $923M | $706M | $565M | $618M | $491M |
| Operating Income | -$70M | -$96M | $56M | -$106M | -$102M |
| Operating Margin | -5.7% | -10.9% | 6.3% | -13.3% | -13.2% |
| Interest Expense | $32M | $21M | $13M | $11M | $14M |
| Income Before Tax | -$106M | -$75M | $4M | -$76M | -$147M |
| Tax Expense | -$27K | $1M | $14M | $5M | -$20M |
| Net Income | -$101M | -$69M | -$9M | -$88M | -$135M |
| Net Margin | -8.2% | -7.8% | -1.0% | -11.0% | -17.5% |
| EPS (Diluted) | $-0.10 | $-0.07 | $-0.01 | $-0.08 | $-0.13 |
| EBITDA | $2M | $23M | $116M | -$26M | -$48M |
| Shares Outstanding | 995M | 1.06B | 1.05B | 1.06B | 1.06B |